In vitro evidence that hsp90 contains two independent chaperone sites  by Young, Jason C et al.
FEBS 19511 FEBS Letters 418 (1997) 139-143 
In vitro evidence that hsp90 contains two independent chaperone sites 
Jason C. Young, Christine Schneider, F. Ulrich Hartl* 
Cellular Biochemistry, Max-Planck-Institut fur Biochemie, Am Klopferspitz 18A, 82152 Martinsried, Germany 
Received 13 October 1997 
Abstract Hsp90 is an abundant and constitutively expressed 
stress protein and molecular chaperone. Here we dissected 
human hsp90 into three major domains to identify the putative 
chaperone site at which hsp90 binds unfolded polypeptide. 
Surprisingly, both the N-terminal and the C-terminal domain 
of hsp90 prevent the aggregation of denatured polypeptides. The 
chaperone activity of the N-domain is inhibited by geldanamycin, 
a specific inhibitor of hsp90-mediated protein refolding. While 
both domains suppress protein aggregation, only the C-domain 
binds an antigenic peptide derived from VSV G. Based on these 
results, hsp90 may be the first chaperone to contain two 
independent chaperone sites with differential specificity. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The cytosolic 90 k D a heat shock protein (hsp90) is a highly 
conserved, constitutively expressed stress protein in eukar-
yotes and prokaryotes. In eukaryotes, hsp90 is known to co-
operate with hsp70/hsp40 and a number of additional factors 
(p60/Stil, p23, p50/cdc37, the immunophilin FKBP52, and 
cyclophilin 40) in the folding of a range of signal transduction 
molecules, including steroid hormone receptors and various 
protooncogenic kinases [1-4]. In vitro experiments have 
shown that hsp90 can act as a general chaperone capable of 
preventing the aggregation of various unfolded polypeptides 
[5]. Refolding of these substrates then depends on the addi-
tional presence of hsp70, an hsp40 homologue and A T P [6]. 
As has been discovered recently, hsp90 is the cellular target of 
the benzoquinoid ansamycin drugs, such as geldanamycin 
(GA) [7], which had previously been thought to specifically 
inhibit the activity of tyrosine kinases. It is now clear that in 
live cells and cell lysates G A inhibits the refolding of these 
kinases and other substrates by hsp90, resulting in their effi-
cient proteosome-mediated degradation [8]. 
Crystal structures of the ~ 25 k D a N-terminal domain of 
hsp90 have recently been reported [9,10]. Consistent with bio-
chemical studies, this domain contains the unique site for the 
high affinity binding of G A [9]. An A T P molecule was also 
observed by crystallography to bind at the same site [10], 
suggesting that GA is an inhibitor of A T P binding to 
hsp90. While there is biochemical evidence for low affinity 
binding of A T P to hsp90 [11,12], an A T P requirement in 
the function of hsp90 has not yet been demonstrated. Models 
for the binding of peptides to the N-terminal domain of hsp90 
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have been proposed [9,13], but have so far not been supported 
by experimental evidence. 
Here we dissected the human hsp90 molecule into inde-
pendently folding domain structures with the goal of estab-
lishing structure-function relationships for this complex chap-
erone protein. Based on in vitro assays using purified hsp90 
fragments and unfolded model substrate proteins, we show 
that hsp90 contains two independent sites with chaperone 
function, one located in the N-terminal domain and the other 
in the C-terminal domain, the latter of which has also been 
implicated in homodimerization of hsp90 [14,15]. The main 
results of this study are summarized in Fig. 1. 
2. Materials and methods 
2.1. Purification of proteins 
Expression and purification of the three hsp90 domains N90, M90 
and C90 have been previously reported [9]. To generate the gluta-
thione-S-transferase (GST) fusion proteins, DNA sequences encoding 
N90, M90 and C90 were ligated into the pGEX-4T-3 vector (Phar-
macia) such that no additional amino acids were encoded between the 
thrombin cleavage site and the hsp90 sequences. The fusion proteins 
were expressed and purified by glutathione affinity chromatography 
(GST Gene Fusion System, Pharmacia). The AN90 and AC90 poly-
peptides were expressed using the pET15b vector (Novagen), and 
purified by chromatography on Q-Sepharose FF or Mono-Q (Phar-
macia) followed by HTP-agarose (BioRad). Hsp90 was purified from 
bovine brain [16]. p60/Stil was expressed as published [17] and puri-
fied by Q-Sepharose chromatography. Bovine rhodanese and firefly 
luciferase were purchased from Sigma, and rabbit reticulocyte lysate 
from Green Hectares (Wisconsin). 
2.2. Measurement of protein aggregation 
Purified rhodanese was denatured at a concentration of 100 uM in 
buffer containing 6 M guanidinium-Cl, 25 mM HEPES-KOH, pH 7.5. 
Denatured rhodanese was rapidly diluted to 0.5 U.M into buffer con-
taining 50 mM KOAc, 25 mM HEPES-KOH, pH 7.5 (buffer F0), plus 
different concentrations of chaperone proteins. The chaperone pro-
teins were exchanged into buffer F0 by chromatography on NAP5 
columns (Pharmacia) immediately before use. Aggregation of rhoda-
nese was monitored over 10 min by the optical density at 320 nm, and 
the data were normalized using the aggregation in buffer alone as the 
standard [18]. Firefly luciferase was denatured at 50 uM under the 
same conditions as rhodanese, and the aggregation at 0.25 uM was 
monitored in the same manner as for rhodanese. 
2.3. Geldanamycin treatment of proteins 
Hsp90, GST-N90 and GST-C90 were incubated at 2 uM in buffer 
F0 containing 18 uM GA (Gibco) for 30 min at room temperature. 
GA was dissolved in dimethyl sulfoxide (DMSO), and the incubation 
mixture contained 1% DMSO. Mock treated protein was similarly 
incubated in buffer F0 with 1% DMSO. Repurification of the proteins 
was found to be necessary to remove trace amounts of DMSO that 
interfered with the aggregation assays (not shown). Hsp90 was repuri-
fied by binding to DE52 (Whatman) for 1 h, washing twice with 10 
volumes of buffer F0, elution with 500 mM KOAc, 25 mM HEPES-
KOH, pH 7.5 for 1 h, then exchanging into buffer F0 with NAP5 
chromatography. The GST fusions were bound to glutathione-Se-
pharose (Pharmacia) for 1 h, washed twice with 10 volumes of buffer 
F0, cleaved with 30 units/ml thrombin (Pharmacia) for 4 h and the 
supernatant used in the aggregation assays. The supernatant con-
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tained the N90 and C90 domains at > 95% purity as determined by 
SDS-PAGE, with no evidence of the full-length GST fusion proteins. 
At the concentration used, thrombin had no effect on rhodanese ag-
gregation (not shown). The concentration of repurified protein was 
measured by Bradford assay (BioRad) and the binding to GA was 
tested as published [7]. 
2.4. Peptide binding 
VSV8 peptide with the sequence RGYVYQGL [19] was synthesized 
using standard Fastmoc protocols on an ABI 430A synthesizer. ]V-e-
aminocaproic acid was coupled to the N-terminus, followed by fluo-
rescein isothiocyanate (FITC). The peptide was cleaved using stand-
ard protocols, purified by C18 reverse phase HPLC and characterized 
by analytical HPLC and MALDI-TOF mass spectrometry. In binding 
assays, the peptide was incubated at 200 U.M in buffer F0 containing 
10 uM hsp90, N90 or C90 for 1 h at 30°C. The reactions were cooled 
to 4°C and separated on a Superose 6 column for hsp90, or a Super-
dex 75 column for N90 and C90. All chromatography was performed 
in buffer F0 at 4°C. One ml fractions were collected and the fluores-
cence intensity at 494 nm excitation and 518 nm emission was meas-
ured in a Fluorolog fluorescence spectrometer. Fractions were then 
analysed by trichloroacetic acid precipitation followed by SDS-
PAGE. 
2.5. Luciferase refolding 
Luciferase was denatured in guanidinium-Cl as above and diluted 
to a concentration of 0.2 uM into buffer F0 containing 10 u,M chap-
erone proteins. After 10 or 30 min incubation, an equal volume of 
reticulocyte lysate supplemented with 12 mM MgOAc and 10 mM 
ATP was added and the reaction incubated at 30°C for 90 min. Lu-
ciferase activity was monitored and normalized to the activity of na-
tive luciferase under identical final conditions as published [8]. 
3. Results and discussion 
Human hsp90 was previously dissected by proteolysis into 
three domains, an N-terminal, a middle and a C-terminal 
domain [9] (see Fig. 1 for domain boundaries). To identify 
which of these contain the known chaperone activity of 
hsp90, proteins corresponding to each of the domains were 
purified after expression in E. coli, either separately (N90, 
M90 and C90) or as fusion proteins with glutathione-S'-trans-
ferase (GST-N90, GST-M90 and GST-C90). In addition, pro-
teins were purified that contained the combined N-terminal 
and middle domains (AC90), and the combined middle and 
C-terminal domains (AN90 (Fig. 1)). All bacterially expressed 
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Fig. 1. Fragments of human hsp90 used in this study and summary 
of the main results. The hsp90 proteins are diagrammed as open 
bars, GST as gray bars. The domain boundaries used are shown as 
amino acid numbers. 
Fig. 2. N- and C-terminal domains of hsp90 prevent aggregation. 
A: Time course of 0.5 uM rhodanese aggregation in buffer (open 
circles), or buffer with 8 uM (filled circles) or 4 uM hsp90 (filled 
squares). B: Time course of 0.5 uM rhodanese aggregation in buffer 
(open circles), or buffer with 8 uM (filled circles) or 4 uM N90 
(filled squares), or 8 uM M90 (filled triangles). C: Time course of 
0.5 uM rhodanese aggregation in buffer (open circles), or buffer 
with 8 u.M (filled circles) or 4 uM C90 (filled squares). D: Aggrega-
tion of 0.5 uM rhodanese after 10 min in buffer with 8 uM GST, 
GST-N90, GST-C90, GST-M90, AN90 or AC90. 
proteins were fully soluble. As a control, full-length native 
hsp90 was purified from bovine brain. 
The chaperone activity of hsp90 can be detected by the 
ability of purified hsp90 to prevent aggregation of unfolded 
polypeptide substrates such as citrate synthase [5] and rhoda-
nese, which was used in this study. Both proteins have a 
pronounced tendency to aggregate upon dilution from the 
denaturant guanidinium-Cl (GdmCl) into a physiological 
buffer solution. This is easily monitored by the increase in 
optical density of the reactions due to light scattering. 
Hsp90 was capable of preventing this aggregation to a degree 
dependent on the concentration of chaperone in the reaction 
(Fig. 2A). Very similar results were obtained with the isolated 
N-terminal domain, N90, which also suppressed rhodanese 
aggregation in a concentration dependent manner (Fig. 2B). 
In contrast, the M90 protein showed no effect on rhodanese 
aggregation (Fig. 2B). Surprisingly, the C-terminal domain, 
C90, also had the capacity to suppress rhodanese aggregation 
and this activity also showed concentration dependence (Fig. 
2C). Parallel results were obtained with the GST fusion pro-
teins. While GST alone and GST-M90 were ineffective, GST-
N90 and GST-C90 could both suppress rhodanese aggrega-
tion to a similar extent as the isolated domains (Fig. 2D). 
Chaperone activities of both GST-N90 and GST-C90 varied 
with the concentration of fusion protein used (data not 
shown). These results suggest that there are binding sites for 
unfolded polypeptides within both the N- and C-terminal do-
mains of hsp90, and that these sites can operate in isolation. 
To further corroborate these conclusions, we tested the con-
structs AN90 and AC90, combining middle and C-terminal 
domains and N-terminal and middle domains, respectively. 
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Both proteins were able to suppress rhodanese aggregation 
(Fig. 2D), supporting the notion that separate chaperone sites 
are present within the N- and C-terminal domains. Moreover, 
the chaperone sites are active while joined to the middle do-
main of hsp90, and therefore are likely to be active in the full-
length hsp90 protein. This is particularly important with re-
gard to the C-terminal domain, which has been implicated in 
the homodimerization of hsp90 [14,15]. Because AN90 be-
haves as a homodimer in gel filtration chromatography (not 
shown), the C-terminal chaperone activity is unlikely to arise 
from inappropriately exposed dimerization sequences of hsp90 
monomers. The chaperone activities of hsp90, N90 and C90 
were unaffected by adding purified p60/Stil (not shown), sug-
gesting that neither of the chaperone sites are normally se-
questered by p60/Stil or other tetratricopeptide repeat pro-
teins. 
The previous identification of the GA binding site within 
the N90 domain suggested that the drug might affect the 
chaperone activity of this domain. To address this question, 
hsp90, N90 and C90 were tested for the ability to suppress 
rhodanese aggregation after preincubation with a 9-fold ex-
cess of GA followed by repurification of the proteins (GA 
binds with high affinity and stays bound upon removal of 
free drug). Proteins subjected to a mock drug treatment 
were also tested for chaperone activity as a control. GA bind-
ing partially inhibited the activity of full-length hsp90 to sup-
press rhodanese aggregation (Fig. 3). Strikingly, the chaper-
one activity of N90 was almost completely inhibited by GA 
treatment (Fig. 3). Hsp90 and N90 repurified after drug treat-
ment were unable to bind GA-affinity beads, in contrast to 
mock treated hsp90 and N90 (not shown), suggesting the ef-
fect on chaperone activity was due to drug remaining tightly 
bound to the proteins. As expected, the C90 protein, which is 
unable to bind GA [9], was only marginally affected by the 
GA treatment (Fig. 3). The partial inhibition by GA of hsp90 
chaperone activity can be interpreted as evidence that at least 
in vitro, the N- and C-terminal domains contribute relatively 
independently to the chaperone activity of full-length hsp90, 
with one site sensitive to the drug and the other not. 
We next addressed the question whether the two chaperone 
sites in hsp90 may have a differential structural specificity for 
target substrates. To this end, binding of a short synthetic 
peptide to N90 and C90 was analyzed. A fragment of vesic-
ular stomatitis virus G protein, termed VSV8, with the se-
quence RGYVYQGL was chosen as a suitable substrate. 
VSV8 was originally identified in live cells as a specific sub-
I 
Fig. 3. Geldanamycin inhibits chaperone activity of the N-terminal 
domain of hsp90. Aggregation of 0.5 uM rhodanese was measured 
after 10 min in the presence of 7 |xM hsp90, 4 u,M N90 or 4 uM 
C90 treated with geldanamycin (GA, +) or subjected to a mock 
treatment (—). The decrease in rhodanese aggregation chaperone ac-
tivity is expressed as a percentage of that observed using mock-
treated chaperone (set to 100%). 
Fig. 4. VSV8 peptide binds to the C-terminal domain of hsp90. A: 
Hsp90 was incubated with a 20-fold excess of FITC-labelled peptide 
and the reaction separated by Superose 6 chromatography (see Sec-
tion 2). FITC fluorescence of column fractions was measured and 
protein content determined by SDS-PAGE and coomassie blue 
staining. SDS-PAGE of each column fraction is shown below the 
corresponding fluorescence intensity. B: N90 incubated with peptide, 
and separated on a Superdex 75 column. C: C90 incubated with 
peptide and separated on a Superdex 75 column. 
strate of GRP94, the endoplasmic reticulum homolog of 
hsp90 that is thought to bind antigenic peptides designated 
for presentation on MHC class I complexes [19-21]. GRP94 
has 48% identity and over 70% similarity to the cytosolic form 
of hsp90, and can be subdivided into domain fragments cor-
responding to those of hsp90 (unpublished observations). 
A 20-fold excess of synthetic peptide, labelled at the amino 
terminus with FITC to allow detection, was incubated with 
hsp90 and the mixture was separated by gel filtration chro-
matography. A peak in FITC fluorescence intensity was de-
tected in the same fractions as hsp90, indicating that the pep-
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Fig. 5. The C-terminal domain of hsp90 maintains denatured luci-
ferase in a folding-competent state. A: Time course of 0.25 uJVI luci-
ferase aggregaton in buffer (open circles), or buffer containing 8 uM 
GST-N90 (filled circles) or GST-C90 (filled squares). B: Denatured 
luciferase was diluted to 0.2 |xM into buffer containing 10 (xM GST, 
GST-N90, GST-M90 or GST-C90 and preincubated for the stated 
time before refolding was initiated by the addition of reticulocyte ly-
sate and Mg-ATP. The amount of refolded luciferase produced is 
presented as a percentage of equivalent native luciferase activity. 
tide was indeed bound by hsp90 (Fig. 4A). A large peak 
corresponding to free peptide was detected at a much later 
elution volume, well resolved from the hsp90 peak (not 
shown). The efficiency of peptide binding by hsp90 was esti-
mated at ~ 5 % , similar to the < 15% previously measured for 
GRP94 [22]. In contrast, when N90 was assayed, there was no 
detectable fluorescence in the column fractions containing the 
protein (Fig. 4B). However, column fractions containing C90 
protein showed a very strong fluorescence signal (Fig. 4C). 
The higher fluorescence intensity observed from peptide 
bound to C90 compared with full-length hsp90 cannot be 
interpreted unambiguously as a higher level of binding, since 
the fluorescence signal may be quenched to some extent by the 
larger hsp90 protein. Nevertheless, the preferential binding of 
this peptide to C90 is initial evidence that the N- and C-ter-
minal domains recognize different polypeptide sequences. 
To further define differences between the N- and C-terminal 
chaperone sites of hsp90, the interaction with another un-
folded polypeptide was examined. Firefly luciferase has been 
shown to interact with hsp90 in reticulocyte lysate and in live 
cells upon thermal denaturation [8]. As shown for rhodanese, 
GdmCl-denatured luciferase aggregated very rapidly upon di-
lution from denaturant. Both GST-N90 and GST-C90 were 
able to suppress luciferase aggregation in this assay (Fig. 5A). 
Consistent with the results obtained with rhodanese, GST 
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alone or GST-M90 had no effect on luciferase aggregation 
(not shown). Because the N- and C-terminal hsp90 domains 
can act on unrelated polypeptides, such as rhodanese and 
luciferase, both domains may be generally involved in the 
function of hsp90 as a cellular chaperone. 
Hsp90 has been shown to maintain unfolded P-galactosi-
dase in a state competent for refolding by subsequently added 
hsp70 and hsp40 homolog [6]. The same activity of hsp90 has 
been reported for luciferase as the unfolded substrate [6], so a 
similar experiment was conducted to examine the activity of 
the N- and C-terminal domains in this refolding assay. 
GdmCl-denatured luciferase was diluted into physiological 
buffer containing either GST, GST-N90, GST-M90 or GST-
C90 and the mixture was incubated for varying times before 
refolding was initiated by adding reticulocyte lysate and Mg-
ATP (reticulocyte lysate contains hsp70 and hsp40 and is 
capable of refolding denatured luciferase). The final yield in 
activity of refolded luciferase was measured after 90 min. As 
expected, when denatured luciferase was diluted into a mix-
ture containing GST, reticulocyte lysate and Mg-ATP without 
preincubation, a high level of luciferase refolding was 
achieved (Fig. 5B, GST, 0 min). In contrast, when unfolded 
enzyme was diluted into buffer containing GST followed by a 
preincubation of 10 or 30 min before the addition of lysate 
and Mg-ATP, very little active luciferase was produced (Fig. 
5B, GST, 10 and 30 min). Similar results were obtained with 
GST-M90 (Fig. 5B, GST-M90). However, when the dena-
tured luciferase was preincubated with GST-C90 for 10 or 
30 min, significant levels of active luciferase were produced 
in the refolding reaction, closer to the refolding observed with 
no preincubation (Fig. 5B, GST-C90). Thus it appears that 
the C-terminal domain of hsp90, like full-length hsp90, can 
maintain an unfolded polypeptide in a folding-competent 
state, indicating that the chaperone activity of this domain 
in preventing aggregation can be utilized for productive fold-
ing. 
Interestingly, GST-N90 inhibited luciferase refolding in the 
control reaction without preincubation (Fig. 5B, GST-N90, 
0 min). Under the same conditions, GST alone or GST-
M90 had no inhibitory effect (Fig. 5B, GST and GST-M90, 
0 min). In other experiments, the isolated N90 also inhibited 
ATP-dependent refolding of luciferase in reticulocyte lysate, 
whereas hsp90 itself produced no inhibition (not shown). This 
effect may be related to the inability of hsp90 cofactors in 
releasing bound polypeptide from N90. 
Based on the crystallographically determined structure of 
N90 [9,10,13], two very different models of peptide binding 
to this domain were proposed. Whereas in one model peptide 
is bound in or near the GA binding site [9], the other proposal 
suggests that the domain dimerizes including peptide in the 
domain interface [13]. Although these models cannot be dis-
tinguished on the basis of the data provided in this study, they 
suggest different mechanisms for the observed inhibition of 
N90 chaperone function by GA (Fig. 3). According to the 
former model, GA could act as a direct competitor for an 
unfolded polypeptide, while in the latter model GA would 
have to inhibit peptide binding allosterically. Such an alloster-
ic mode of inhibition would be consistent with the view that 
GA functions as a competitive inhibitor of ATP [10]. How-
ever, addition of high concentrations of ATP (1 mM) did not 
inhibit the chaperone function of the N-terminal domain (not 
shown), which was significantly inhibited by concentrations of 
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G A as low as 18 u M followed by removal of excess drug (Fig. 
3). It has been proposed that additional factors, such as p23, 
interact with hsp90 in an ATP-dependent manner [23]. Their 
effect on the chaperone activity of the N90 domain remains to 
be investigated. 
The observed chaperone activity of C90 suggests a biolog-
ical function beyond that of a simple dimerization domain. 
Since the C90 domain binds the antigenic VSV8 peptide, it is 
possible that the homologous domain of G R P 9 4 contains the 
binding site for various antigenic peptide substrates. The abil-
ity of a C-terminal hsp90 fragment to enhance the activity of 
certain basic helix-loop-helix transcription factors in vitro 
[24,25] may also involve the chaperone activity of this domain. 
The extent to which the two putative chaperone sites in 
hsp90 may be utilized physiologically remains to be estab-
lished. Nevertheless, it is interesting to speculate on how the 
two sites may interact in a biological setting. Fo r example, the 
in vivo effects of G A may be explained by its inhibitory effect 
on the chaperone activity of the N-terminal domain, which 
may result in the accumulation of hsp90 substrate polypep-
tides bound to the C-terminal domain. These questions will be 
the subject of future experiments. 
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